MedTrace Logo

Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

NCT02670616 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-10-22

No results posted yet for this study

Summary

This study was conducted to evaluate the complete response rate of Ibrutinib + R-CHOP in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.

Conditions

  • Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

Interventions

DRUG

Ibrutinib

560 mg by mouth daily on day 1-21 per each cycle

DRUG

Rituximab

375 mg/m2 IV, day 1

DRUG

Cyclophosphamide

750 mg/m2 IV day 1

DRUG

Doxorubicin

50 mg/m2 IV day 1

DRUG

vincristine

1.4 mg/m2 IV on day 1

DRUG

Prednisolone

100mg per day on day 1-5

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Won seog KIM, MD,Ph.D. · Samsung Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-01
Primary Completion
2020-06-30
Completion
2020-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02670616 on ClinicalTrials.gov